Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen-receptor-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01394211
What this trial is testing

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMale Breast Cancer+4 more
University of Arizona 2
Testing effectiveness (Phase 2)WithdrawnNCT04038489
What this trial is testing

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
University of Virginia
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Early research (Phase 1)Study completedNCT03544125
What this trial is testing

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeHER2/Neu Negative+3 more
OHSU Knight Cancer Institute 3
Testing effectiveness (Phase 2)Study completedNCT05163106
What this trial is testing

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Who this might be right for
Breast CancerHER2-negative Breast CancerER-positive Breast Cancer+3 more
University Hospital, Akershus 85
Early research (Phase 1)Active Not RecruitingNCT04188548
What this trial is testing

LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+1 more
Eli Lilly and Company 379
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)Active Not RecruitingNCT02238808
What this trial is testing

See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers

Who this might be right for
Estrogen Receptor Positive Breast Cancer
AHS Cancer Control Alberta 19
Not applicableStudy completedNCT05392985
What this trial is testing

Detection and Analysis of MBC With Heterogeneous ER Expression

Who this might be right for
Breast Cancer
Fudan University 51
Testing effectiveness (Phase 2)Looking for participantsNCT07612215
What this trial is testing

Elacestrant in Advanced Triple Positive Breast Cancer

Who this might be right for
ER Positive, HER2 Positive Breast Cancer
NYU Langone Health 50
Testing effectiveness (Phase 2)Ended earlyNCT01147016
What this trial is testing

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 8
Testing effectiveness (Phase 2)Ended earlyNCT04577963
What this trial is testing

Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Triple Negative Breast CancerEndometrial CancerSolid Tumor, Unspecified, Adult+1 more
Hutchmed 52
Large-scale testing (Phase 3)Looking for participantsNCT05879926
What this trial is testing

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Who this might be right for
Breast Cancer
NRG Oncology 3,960
Large-scale testing (Phase 3)Study completedNCT00938652
What this trial is testing

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 519
Testing effectiveness (Phase 2)Study completedNCT01560416
What this trial is testing

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284
What this trial is testing

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Who this might be right for
ER+HER2- Breast Cancer
West China Hospital 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT05607004
What this trial is testing

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Who this might be right for
Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast Cancer+1 more
Atossa Therapeutics, Inc. 87
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Testing effectiveness (Phase 2)Active Not RecruitingNCT04568616
What this trial is testing

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

Who this might be right for
Breast CancerER Positive Breast Cancer
Dartmouth-Hitchcock Medical Center 178
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Next Page